PGG glucan - Biothera

Drug Profile

PGG glucan - Biothera

Alternative Names: B-glucan PGG; BTH-1677; Complement receptor type 3 modulator - Biothera; CR3 modulator - Biothera; Imprime PGG; Soluble beta glucan - Biothera

Latest Information Update: 27 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; Mayo Clinic; Merck
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Fc gamma receptor IIA modulators; Immunostimulants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Breast cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Phase I Pancreatic cancer
  • Preclinical Head and neck cancer; Myelosuppression
  • Research Follicular lymphoma
  • Suspended Infections
  • No development reported Stem cell mobilisation

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer and a clinical study in Healthy volunteers presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 30 Jan 2017 Biothera terminates a phase III trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line or greater) in USA, France, Germany and Puerto Rico due to challenges in patient enrolment (NCT01309126)
  • 06 Dec 2016 Biothera and Merck plan a phase II trial for Head and neck cancer (Combination therapy, Second line therapy or greater) in Q2 2017(Biothera website, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top